Cyclacel Pharmaceuticals Inc. (CYCC) announced Monday morning that preclinical data of CYC065 showed that it substantially inhibited growth, triggered apoptosis, and induced anaphase catastrophe in murine and human lung cancer cells with known high metastatic potential.
Cyclacel Pharmaceuticals gapped up at the open Monday and has spiked higher in the last 15 minutes on increased volume. Shares are now up 2.13 at $5.81. The stock has surged to over a 1-month high and has re-crossed its 50 and 200-day moving averages.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.